Navigation Links
Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
Date:5/6/2008

en evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

Phase 2 Study Details

The Phase 2 study is a two-arm, randomized, controlled 100-patient trial of first-line treatment of metastatic CRC. The objective of the Phase 2 trial is to compare the safety and efficacy of intravenous picoplatin given once every four weeks in the FOLPI regimen with oxaliplatin in combination with 5- fluorouracil and leucovorin in the modified FOLFOX-6 regimen and to evaluate clinical activity. Poniard expects to generate proof-of-concept data from the Phase 2 trial demonstrating that picoplatin has an improved safety profile. This trial could position picoplatin as the preferred platinum agent for the first-line treatment of metastatic colorectal cancer and could potentially enable a Phase 3 study.

-- Poniard initiated the Phase 2 trial in November 2007 based on clinical

activity and promising safety data observed in its 50-patient, Phase 1

dose-escalation study of picoplatin in the FOLPI regimen as a

first-line treatment for metastatic CRC. Results of the Phase 1 trial

were presented at the ASCO Gastrointestinal Cancers Satellite Symposium

in January and demonstrated that picoplatin has a manageable toxicity

in combination with 5-fluorouracil and leucovorin Picoplatin did not

cause severe neurotoxicity (Grade 3 or higher), as is commonly seen in

metastatic CRC patients treated with oxaliplatin as part of the FOLFOX

regimen. Current National Comprehensive Cancer Network (NCCN) Clinical

Practice Guidelines in Oncology for colon cancer encourage the

discontinuation of FOLFOX after three months of therapy or sooner if

significant neurotoxicity develops (Grade
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
2. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
3. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
4. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
5. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
(Date:7/12/2014)... The "North American Interventional ... by Angioplasty Balloon (Plain/Old, Cutting), Stent ... Filter (Retrievable), Endovascular Stent Graft - ... the major market drivers, restraints, and ... , Browse 108 market data tables ...
(Date:7/12/2014)... fastest-growing mobile technology is LTE (Long Term Evolution). The ... to grow due to the rapid evolution of LTE. ... traffic, which is a major driver for the Communications ... equipment comply with industry standards, and services which meet ... is estimated to grown from $3.75 billion in 2013 ...
(Date:7/12/2014)... Burn injuries increase in the summer as people gather around ... those most vulnerable to these seasonal fire hazards: children. ... burned by putting their hands on the side of cooking ... at Loyola University Medical Center in Maywood, Ill., said in ... you play with fire, you get burned, is true -- ...
(Date:7/12/2014)... 2014 Using and carrying around a ... inventors from Ashland, Va., decided that there needed to ... us to conceive of our design," he said. , ... KOVER, which provides an inconspicuous way to use and ... well as promotes comfort and peace of mind. Producible ...
(Date:7/12/2014)... OH (PRWEB) July 12, 2014 Wright & ... against DePuy Orthopedics , Inc., a subsidiary of Johnson & ... he suffers chronic pain after receiving a metal-on-metal DePuy Pinnacle ... later to remove the artificial hip implant. The DePuy hip ... Court, Northern District of Texas (Case No. 3:14-cv-2427) where ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5
... Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China Yingxia" ... industry engaged in the,development, manufacture and distribution of ... in the People,s Republic,of China ("PRC"), today reported ... 31, 2008., First Quarter 2008 Highlights, ...
... goal of tailoring cancer treatment for each individual, researchers ... suggesting a simple blood test can help doctors more ... cancer. , It can take several weeks and sometimes ... working because it can take that long to observe ...
... protein called IGF-1R in patients with gastrointestinal stromal tumors ... responsive to the drug imatinib mesylate (known as Gleevec), ... the Fox Chase Cancer Center in Philadelphia. Preliminary ... might respond well to agents in development for treatment-resistant ...
... Digital Power,Corporation (Amex: DPW ) (herein "Digital Power") ... March 31, 2008., Digital Power reported revenue of ... of 15.6% from $2,742,000 for the same quarter,last year. ... of 2008 was,reported, compared to an operating profit of ...
... 15 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... company with its principal operations,in the People,s Republic ... quarter ended March 31, 2008, the Company,s third ... A 10QSB Form was filed for the quarter,with ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... Vice President, Quality. He will have,responsibilities in the ... manufacturing operations and preclinical / clinical,product candidates. Mr. ... at Telik, Inc. in Palo Alto, California, where ...
Cached Medicine News:Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Protein predicts Gleevec resistance in gastrointestinal tumors 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12Health News:Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality 2
... The ISOPLATER® is an automatic petri ... streak and stack up to 180 ... Automated streaking results in substantial cost ... improves isolation rates, standardizes streaking procedures ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... by Laborie, a leading producer ... credible tracings. ICS recognized Urodynamics ... parameters. Designed especially for the ... to be quick, efficient and ...
... diagnostic capabilities combined with ease of use ... in its class. Ideal for office or ... system for Uroflowmetry, cystometry, leak point pressure, ... are available which make the OM-5 flexible ...
Medicine Products: